Chronic Granulomatous Disease (CGD) Management Market Snapshot (2023 to 2033)
The global chronic Granulomatous disease (CGD) management market is expected to garner a market value of US$ 1.31 Billion in 2023 and is expected to accumulate a market value of US$ 2.11 Billion by registering a CAGR of 4.9% in the forecast period 2023 to 2033. Growth of the chronic Granulomatous disease (CGD) management market can be attributed to increasing research and development activities by key players for developing medications. the market for chronic Granulomatous disease (CGD) management registered a CAGR of 3.3% in the historical period 2018 to 2022.
The chronic granulomatous disease is a severe genetic condition that is passed down through the generations. People who suffer from this disease have weakened immune systems, making them subject to chronic inflammation and bacterial and fungal infections. The signs and symptoms of this condition appear in infancy or early childhood.
Report Attribute
Details
Expected Market Value (2023)
US$ 1.31 Billion
Anticipated Forecast Value (2033)
US$ 2.11 Billion
Projected Growth Rate (2023 to 2033)
4.9% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Chronic Granulomatous Disease (CGD) Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Chronic Granulomatous disease (CGD) management reflected a value of 3.3% during the historical period, 2018 to 2022.
Chronic granulomatous disease or CGD is a kind of disorder under which white blood cells (phagocytes) are unable to kill certain types of bacteria and fungi. It is basically an inherited primary immunodeficiency disease caused by defects in the NADPH oxidase complex resulting in respiratory bursts in phagocytic leukocytes. The patients might develop skin infections, lymph node infections, pneumonia, lung infections, liver infections, gastrointestinal inflammation, or other infections. Thus, with the unique nature of CGD, the development of medications has increased rapidly. In the upcoming years, technological integration and research will boost the market for CGD management market.
Thus, the market for Chronic Granulomatous disease (CGD) management is expected to register a CAGR of 4.9% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Chronic Granulomatous Disease (CGD) Management Market?
Research and development activities boosting the growth of the CGD market
The fact that 1 in 200000 or 250000 people suffer from CGD makes it a rare disease. In addition,the signs and symptoms of this illness differ from person to person. Frequent bacterial and fungal infections, swollen lymph nodes, recurrent diarrhoea, and abscesses involving the liver, lungs, spleen, bones, or skin are some of the most prevalent signs and symptoms.
The market is expected to rise due to factors such as the rising prevalence of rare illnesses, increased healthcare spending in developed economies, and increased research and development activities.
Changing lifestyles along with advancements in technology to innovate medication accelerating market growth
Factors such as the changes adopted in lifestyle and alterations in food habits is further expected to accelerate the overall growth of the chronic granulomatous disease treatment market within the forecast period. Additionally, the growing prevalence of rare diseases in some developing countries and increasing research and development activities boost the overall market’s demand.
Additionally, the advancement in technology and rising government funding for the healthcare sector are to further extend suitable opportunities for the growth of the chronic granulomatous disease treatment market in the near future.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Chronic Granulomatous Disease (CGD) Management Market?
Expensive nature of the treatment along with the lack of awareness hampering the market growth
The unavailability of effective treatments for different types of chronic granulomatous disease along with the high cost associated with treatment and diagnostic tests of chronic granulomatous disease is anticipated to most likely obstruct the growth of the chronic granulomatous disease treatment market in the coming years.
The lack of awareness about the disease in developing and underdeveloped economies can be one of the challenging factors within the forecast period. For example, Genetic testing might cost anything from $100 to $2,000. All these factors are hampering the growth of the CGD market.
Region-Wise Insights
Rising Prevalence of CGD Boosting Market Growth in North America?
Research and development activities create lucrative opportunities for market growth
The North American region is expected to hold the largest market share for the CGD market. This is due to a well-developed healthcare sector, the rising prevalence of rare diseases, the steadily growing occurrence of chronic granulomatous disease (CGD), and a relatively large number of research and development activities in the North American region.
According to a 2017 report published by the National Center for Biotechnology Information (NCBI), CGD affects 1 in 200,000 to 1 in 250,000 births in the United States. This, in turn, has created lucrative opportunities for innovating medication for treating the ailment. Furthermore, increased government support for the healthcare sector in the region is another factor driving the growth of the market. Thus, the North American region is expected to dominate the Chronic Granulomatous Disease by possessing a 45% market share in 2023.
Expenditure on Research Activities Bolstering CGD Market Growth in Europe?
Development of the healthcare sector shaping the landscape for the CGD market
The rising prevalence of rare diseases, as well as increased research and development activities, are driving market growth in this region. According to Eurostat, gross domestic expenditure (GERD) on research and development was EUR 303 billion in 2016.
In addition, increasing government funding for the healthcare sector and increasing research and development activities are changing the landscape for the CGD market. With the strong presence of key players in the region, Europe is expected to hold a 35% market share in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Presence of X-linked CGD in Males Bolstering Segment Growth?
Detection of symptoms in early age advancing growth of X-linked CGD
Based on the Type, the market is segmented into X-Linked Chronic Granulomatous Disease and Autosomal Recessive Chronic Granulomatous Disease.
Patients with X-linked CGD often develop infections in their first ten years of life, and around 40% of them die before they reach the age of 35. Males are more likely than females to develop the chronic granulomatous disease. Approximately two-thirds of people in North American and European research had the X-linked recessive type of the disease. CGD is present at birth because it is a hereditary condition.
CGD symptoms normally appear throughout childhood or early adolescence, but they can sometimes be delayed until the early adolescent years. The earliest symptoms have been found to appear in adults in a few cases. The chronic granulomatous disease affects approximately four to five people in every Billion people globally.
Thus, the X-Linked Chronic Granulomatous Disease segment is expected to possess 52% market for the CGD market in 2023.
Effectiveness of Antibiotic Medication Increasing Dependency on Trimethoprim?
Trimethoprim exhibiting promising results for treating CBD
Based on the Treatment, the market is segmented into Infection Management, Trimethoprim, Sulfamethoxazole, Itraconazole, Interferon-gamma, Stem cell transplantation, and others. Trimethoprim is expected to hold the largest share of the CGD market in 2023.
Continuous antibiotic medication to help prevent infections, such as trimethoprim for bacterial infections and itraconazole for fungal infections, is used to treat chronic granulomatous illness. Antibiotics are usually required for infections. Corticosteroid medications can also help with granulomatous consequences. In some people with CGD, bone marrow transplants have been shown to be beneficial.
Thus, Trimethoprim is expected to possess a 40% market share for the CGD market in 2023.
Market Key Players Promoting Products and Services in Hospitals Due to Its Increasing Convenience?
Hospitals increasing accessibility for treatment of CBD management market
Based on the end-user, the market is segmented into Hospitals, Clinical laboratories, and Others. The hospital segment is expected to hold the largest market share in 2023.
This is due to the growing number of Chronic Granulomatous Disease patients increasing the treatments of Chronic Granulomatous Disease in hospitals. Hospitals are a significant part of the healthcare industry and a key source of revenue for the overall industry, which stimulates research and innovation.
As a result, a number of firms devote large resources to promoting their products and services among hospitals, both in terms of revenue and marketing tactics. Due to these factors, strategic decisions made in the hospital sector can have an impact on other sectors of the healthcare industry, providing them significant control over contract conditions with suppliers, service providers, and distributors.
These are the key factors that are expected to drive the growth of the hospital segment in the Chronic Granulomatous Disease Market during the forecast period. Thus, hospitals are expected to possess a 40% market share in the CBD management market.
Market Competition
Key players in the chronic Granulomatous disease (CGD) management market are Clinigen Group plc, Orchard Therapeutics plc, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA
Pfizer Inc, a key player in the CGD management market is investing in extensive research for innovating medications to reduce the efficiency of the symptoms caused by CGD.
Novartis AG, another key player in the CGD management market is focusing on integrating technology and commercializing medication for CGD management.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 1.31 Billion
Market Value in 2033
US$ 2.11 Billion
Growth Rate
CAGR of 4.9% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Type
Diagnosis
Treatment
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)
Key Countries Profiled
The United States of America
Canada
Brazil
Argentina
Germany
The United Kingdom
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
Association of Southeast Asian Nations (ASEAN)
GCC
South Africa
Key Companies Profiled
Clinigen Group plc
Orchard Therapeutics plc2032
Horizon Therapeutics plc
ViroMed. Co. Ltd
Bellicum Pharmaceuticals, Inc
Pfizer Inc
Hoffmann-La Roche Ltd
Novartis AG
Lonza
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson Services, Inc
Merck KGaA
Customization
Available Upon Request
Key Segments Profiled in the Chronic Granulomatous Disease (CGD) Management Industry Survey
Type:
X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease
Diagnosis:
Neutrophil Function Tests
Genetic Testing
Prenatal Testing
Treatment:
Infection Management
Trimethoprim
Sulfamethoxazole
Itraconazole
Interferon-gamma
Stem Cell Transplantation
Others
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA
Frequently Asked Questions
What is the market size in 2023?
The industry will reach a market value of US$ 1.31 billion in 2023.
What was the projected growth rate from 2018 to 2022?
The market witnessed 3.3% historically.
What is North America's expected share in 2023?
North America is likely to generate 45% revenue in 2023.
How market for Europe is projected to grow in 2023?
Europe's market size is expected to hold a 35% share in 2023.
What is the CAGR from 2023 to 2033?
The market is expected to record a 4.9% CAGR until 2033.
Table of Content
1. Executive Summary | Chronic Granulomatous Disease (CGD) Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. X-Linked Chronic Granulomatous Disease
5.3.2. Autosomal Recessive Chronic Granulomatous Disease
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
6.3.1. Neutrophil Function Tests
6.3.2. Genetic Testing
6.3.3. Prenatal Testing
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
7.3.1. Infection Management
7.3.2. Trimethoprim
7.3.3. Sulfamethoxazole
7.3.4. Itraconazole
7.3.5. Interferon-gamma
7.3.6. Stem Cell Transplantation
7.3.7. Others
7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033
8.3.1. Hospitals
8.3.2. Clinical Laboratory
8.3.3. Homecare
8.3.4. Others
8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Type
10.2.3. By Diagnosis
10.2.4. By Treatment
10.2.5. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Diagnosis
10.3.4. By Treatment
10.3.5. By End-User
10.4. Key Takeaways
11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Type
11.2.3. By Diagnosis
11.2.4. By Treatment
11.2.5. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Diagnosis
11.3.4. By Treatment
11.3.5. By End-User
11.4. Key Takeaways
12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. US
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Type
12.2.3. By Diagnosis
12.2.4. By Treatment
12.2.5. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Diagnosis
12.3.4. By Treatment
12.3.5. By End-User
12.4. Key Takeaways
13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Type
13.2.3. By Diagnosis
13.2.4. By Treatment
13.2.5. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Diagnosis
13.3.4. By Treatment
13.3.5. By End-User
13.4. Key Takeaways
14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Type
14.2.3. By Diagnosis
14.2.4. By Treatment
14.2.5. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Diagnosis
14.3.4. By Treatment
14.3.5. By End-User
14.4. Key Takeaways
15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Type
15.2.3. By Diagnosis
15.2.4. By Treatment
15.2.5. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. By Diagnosis
15.3.4. By Treatment
15.3.5. By End-User
15.4. Key Takeaways
16. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Type
16.2.3. By Diagnosis
16.2.4. By Treatment
16.2.5. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Type
16.3.3. By Diagnosis
16.3.4. By Treatment
16.3.5. By End-User
16.4. Key Takeaways
17. Key Countries Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Type
17.1.2.2. By Diagnosis
17.1.2.3. By Treatment
17.1.2.4. By End-User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Type
17.2.2.2. By Diagnosis
17.2.2.3. By Treatment
17.2.2.4. By End-User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Type
17.3.2.2. By Diagnosis
17.3.2.3. By Treatment
17.3.2.4. By End-User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Type
17.4.2.2. By Diagnosis
17.4.2.3. By Treatment
17.4.2.4. By End-User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Type
17.5.2.2. By Diagnosis
17.5.2.3. By Treatment
17.5.2.4. By End-User
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Type
17.6.2.2. By Diagnosis
17.6.2.3. By Treatment
17.6.2.4. By End-User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Type
17.7.2.2. By Diagnosis
17.7.2.3. By Treatment
17.7.2.4. By End-User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Type
17.8.2.2. By Diagnosis
17.8.2.3. By Treatment
17.8.2.4. By End-User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Type
17.9.2.2. By Diagnosis
17.9.2.3. By Treatment
17.9.2.4. By End-User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Type
17.10.2.2. By Diagnosis
17.10.2.3. By Treatment
17.10.2.4. By End-User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Type
17.11.2.2. By Diagnosis
17.11.2.3. By Treatment
17.11.2.4. By End-User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Type
17.12.2.2. By Diagnosis
17.12.2.3. By Treatment
17.12.2.4. By End-User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Type
17.13.2.2. By Diagnosis
17.13.2.3. By Treatment
17.13.2.4. By End-User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Type
17.14.2.2. By Diagnosis
17.14.2.3. By Treatment
17.14.2.4. By End-User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Type
17.15.2.2. By Diagnosis
17.15.2.3. By Treatment
17.15.2.4. By End-User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Type
17.16.2.2. By Diagnosis
17.16.2.3. By Treatment
17.16.2.4. By End-User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Type
17.17.2.2. By Diagnosis
17.17.2.3. By Treatment
17.17.2.4. By End-User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Type
17.18.2.2. By Diagnosis
17.18.2.3. By Treatment
17.18.2.4. By End-User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Type
17.19.2.2. By Diagnosis
17.19.2.3. By Treatment
17.19.2.4. By End-User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Type
17.20.2.2. By Diagnosis
17.20.2.3. By Treatment
17.20.2.4. By End-User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Type
17.21.2.2. By Diagnosis
17.21.2.3. By Treatment
17.21.2.4. By End-User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Type
18.3.3. By Diagnosis
18.3.4. By Treatment
18.3.5. By End-User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Clinigen Group plc
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Orchard Therapeutics plc2032
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Horizon Therapeutics plc
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. ViroMed. Co. Ltd
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Bellicum Pharmaceuticals, Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Pfizer Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. F. Hoffmann-La Roche Ltd
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Novartis AG
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Lonza
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. GlaxoSmithKline plc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Eli Lilly and Company
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Johnson & Johnson Services, Inc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Merck KGaA
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 5: Global Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Type, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 9: North America Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 10: North America Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by Type, 2018 to 2033
Table 13: Latin America Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 14: Latin America Value (US$ Million) Forecast by Treatment+, 2018 to 2033
Table 15: Latin America Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Value (US$ Million) Forecast by Type, 2018 to 2033
Table 18: Europe Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 19: Europe Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 20: Europe Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 21: South Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia Value (US$ Million) Forecast by Type, 2018 to 2033
Table 23: South Asia Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 24: South Asia Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 25: South Asia Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 26: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: East Asia Value (US$ Million) Forecast by Type, 2018 to 2033
Table 28: East Asia Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 29: East Asia Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 30: East Asia Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 31: Oceania Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Oceania Value (US$ Million) Forecast by Type, 2018 to 2033
Table 33: Oceania Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 34: Oceania Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 35: Oceania Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 36: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 37: MEA Value (US$ Million) Forecast by Type, 2018 to 2033
Table 38: MEA Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 39: MEA Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 40: MEA Value (US$ Million) Forecast by End-User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 3: Global Value (US$ Million) by Treatment, 2023 to 2033
Figure 4: Global Value (US$ Million) by End-User, 2023 to 2033
Figure 5: Global Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 10: Global Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 11: Global Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 12: Global Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 13: Global Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 14: Global Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 15: Global Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 16: Global Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 17: Global Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 18: Global Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 19: Global Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 20: Global Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 21: Global Attractiveness by Type, 2023 to 2033
Figure 22: Global Attractiveness by Diagnosis, 2023 to 2033
Figure 23: Global Attractiveness by Treatment, 2023 to 2033
Figure 24: Global Attractiveness by End-User, 2023 to 2033
Figure 25: Global Attractiveness by Region, 2023 to 2033
Figure 26: North America Value (US$ Million) by Type, 2023 to 2033
Figure 27: North America Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 28: North America Value (US$ Million) by Treatment, 2023 to 2033
Figure 29: North America Value (US$ Million) by End-User, 2023 to 2033
Figure 30: North America Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 37: North America Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 38: North America Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 39: North America Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 40: North America Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 41: North America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 42: North America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 43: North America Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 44: North America Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 45: North America Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 46: North America Attractiveness by Type, 2023 to 2033
Figure 47: North America Attractiveness by Diagnosis, 2023 to 2033
Figure 48: North America Attractiveness by Treatment, 2023 to 2033
Figure 49: North America Attractiveness by End-User, 2023 to 2033
Figure 50: North America Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Value (US$ Million) by Type, 2023 to 2033
Figure 52: Latin America Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 53: Latin America Value (US$ Million) by Treatment, 2023 to 2033
Figure 54: Latin America Value (US$ Million) by End-User, 2023 to 2033
Figure 55: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 60: Latin America Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 61: Latin America Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 62: Latin America Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 63: Latin America Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 64: Latin America Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 65: Latin America Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 66: Latin America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 67: Latin America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 68: Latin America Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 69: Latin America Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 70: Latin America Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 71: Latin America Attractiveness by Type, 2023 to 2033
Figure 72: Latin America Attractiveness by Diagnosis, 2023 to 2033
Figure 73: Latin America Attractiveness by Treatment, 2023 to 2033
Figure 74: Latin America Attractiveness by End-User, 2023 to 2033
Figure 75: Latin America Attractiveness by Country, 2023 to 2033
Figure 76: Europe Value (US$ Million) by Type, 2023 to 2033
Figure 77: Europe Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 78: Europe Value (US$ Million) by Treatment, 2023 to 2033
Figure 79: Europe Value (US$ Million) by End-User, 2023 to 2033
Figure 80: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 85: Europe Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 86: Europe Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 87: Europe Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 88: Europe Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 89: Europe Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 90: Europe Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 91: Europe Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 92: Europe Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 93: Europe Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 94: Europe Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 95: Europe Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 96: Europe Attractiveness by Type, 2023 to 2033
Figure 97: Europe Attractiveness by Diagnosis, 2023 to 2033
Figure 98: Europe Attractiveness by Treatment, 2023 to 2033
Figure 99: Europe Attractiveness by End-User, 2023 to 2033
Figure 100: Europe Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Value (US$ Million) by Type, 2023 to 2033
Figure 102: South Asia Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 103: South Asia Value (US$ Million) by Treatment, 2023 to 2033
Figure 104: South Asia Value (US$ Million) by End-User, 2023 to 2033
Figure 105: South Asia Value (US$ Million) by Country, 2023 to 2033
Figure 106: South Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 110: South Asia Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 111: South Asia Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 112: South Asia Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 113: South Asia Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 114: South Asia Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 115: South Asia Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 116: South Asia Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 117: South Asia Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 118: South Asia Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 119: South Asia Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 120: South Asia Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 121: South Asia Attractiveness by Type, 2023 to 2033
Figure 122: South Asia Attractiveness by Diagnosis, 2023 to 2033
Figure 123: South Asia Attractiveness by Treatment, 2023 to 2033
Figure 124: South Asia Attractiveness by End-User, 2023 to 2033
Figure 125: South Asia Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Value (US$ Million) by Type, 2023 to 2033
Figure 127: East Asia Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 128: East Asia Value (US$ Million) by Treatment, 2023 to 2033
Figure 129: East Asia Value (US$ Million) by End-User, 2023 to 2033
Figure 130: East Asia Value (US$ Million) by Country, 2023 to 2033
Figure 131: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 135: East Asia Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 136: East Asia Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 137: East Asia Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 138: East Asia Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 139: East Asia Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 140: East Asia Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 141: East Asia Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 142: East Asia Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 143: East Asia Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 144: East Asia Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 145: East Asia Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 146: East Asia Attractiveness by Type, 2023 to 2033
Figure 147: East Asia Attractiveness by Diagnosis, 2023 to 2033
Figure 148: East Asia Attractiveness by Treatment, 2023 to 2033
Figure 149: East Asia Attractiveness by End-User, 2023 to 2033
Figure 150: East Asia Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Value (US$ Million) by Type, 2023 to 2033
Figure 152: Oceania Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 153: Oceania Value (US$ Million) by Treatment, 2023 to 2033
Figure 154: Oceania Value (US$ Million) by End-User, 2023 to 2033
Figure 155: Oceania Value (US$ Million) by Country, 2023 to 2033
Figure 156: Oceania Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 160: Oceania Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 161: Oceania Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 162: Oceania Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 163: Oceania Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 164: Oceania Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 165: Oceania Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 166: Oceania Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 167: Oceania Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 168: Oceania Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 169: Oceania Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 170: Oceania Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 171: Oceania Attractiveness by Type, 2023 to 2033
Figure 172: Oceania Attractiveness by Diagnosis, 2023 to 2033
Figure 173: Oceania Attractiveness by Treatment, 2023 to 2033
Figure 174: Oceania Attractiveness by End-User, 2023 to 2033
Figure 175: Oceania Attractiveness by Country, 2023 to 2033
Figure 176: MEA Value (US$ Million) by Type, 2023 to 2033
Figure 177: MEA Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 178: MEA Value (US$ Million) by Treatment, 2023 to 2033
Figure 179: MEA Value (US$ Million) by End-User, 2023 to 2033
Figure 180: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 181: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 182: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: MEA Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 185: MEA Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 186: MEA Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 187: MEA Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 188: MEA Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 189: MEA Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 190: MEA Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 191: MEA Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 192: MEA Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 193: MEA Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 194: MEA Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 195: MEA Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 196: MEA Attractiveness by Type, 2023 to 2033
Figure 197: MEA Attractiveness by Diagnosis, 2023 to 2033
Figure 198: MEA Attractiveness by Treatment, 2023 to 2033
Figure 199: MEA Attractiveness by End-User, 2023 to 2033
Figure 200: MEA Attractiveness by Country, 2023 to 2033
